Stopped: Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized.
The primary purpose of this study is to determine if the long-term use of SPD489 (40, 80, 100, 120, 140, and 160mg) administered as a daily morning is safe and tolerable.
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at 52 Weeks
Timeframe: Basline and 52 weeks
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at 52 Weeks
Timeframe: Baseline and 52 weeks
Columbia-Suicide Severity Rating Scale (C-SSRS)
Timeframe: Up to 52 weeks
Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at 52 Weeks
Timeframe: Baseline and 52 weeks
Change From Baseline in Simpson Angus Scale (SAS) Total Score at 52 Weeks
Timeframe: Baseline and 52 weeks
Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at 52 Weeks
Timeframe: Baseline and 52 weeks
Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) at 52 Weeks
Timeframe: Baseline and 52 weeks
Change From Baseline in Clinical Evaluation of Harmful Behavior (CEHB) Scale at 52 Weeks
Timeframe: Baseline and 52 weeks
Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at 52 Weeks
Timeframe: Baseline and 52 weeks